Navigation Links
MannKind Corporation Response to Recent Market Events
Date:3/10/2008

endent data safety monitoring board that meets at regular intervals to review safety data. To date, the data safety monitoring board has fully endorsed continuation of the trials as planned.

MannKind has also undertaken a more comprehensive examination of the toxicology profile of Technosphere(R) Insulin than has been reported for any other inhaled insulin. Last year, MannKind completed a two-year carcinogenicity study in rats in which Technosphere(R) Insulin, and large doses of Technosphere(R) particles alone, were well tolerated after daily inhalations for 104 consecutive weeks. There were no indications in these studies that either Technosphere(R) Insulin or Technosphere(R) particles alone had any carcinogenic potential or caused any cellular proliferation in the lungs. MannKind also recently completed a six-month carcinogenicity study in transgenic mice, finding no macroscopic indications of carcinogenicity in animals given daily subcutaneous injections of Technosphere(R) Insulin or Technosphere(R) particles for 26 consecutive weeks. In addition, MannKind plans to submit data from over 100 preclinical studies supporting the safety of our product, the vast majority of which have already been completed.

The pharmacokinetic profile of Technosphere(R) Insulin sets it apart from all other insulin products. The large surface area of the lung provides unique access to the circulatory system, but the sugar-based carriers used by others simply cannot convey insulin to the bloodstream any faster than that achieved by a subcutaneous injection of a rapid-acting insulin analog. In contrast, the pH-sensitive Technosphere(R) particles dissolve upon contact with the lung surface, releasing insulin monomers that rapidly enter the bloodstream. As described in recent publications in the Journal of Diabetes Science and Technology, MannKind's Technosphere(R) Insulin achieves peak insulin levels within 12-14 minutes of administration, effectively mimicking the release o
'/>"/>

SOURCE MannKind Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. MannKind to Present at the UBS Global Life Sciences Conference
2. MannKind Corporation Raises $250 Million in Self Managed Registered Direct Offerings of Common Stock
3. MannKind Announces Positive Results from a Phase 1a Study of a GLP-1 Formulation
4. MannKind to Present at the Piper Jaffray Healthcare Conference
5. MannKind to Present at the Wachovia 2008 Healthcare Conference
6. MannKind to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
7. MannKind Corporation to Hold Fourth Quarter Financial Results Conference Call on March 4, 2008
8. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
9. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
10. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
11. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... April 27, 2015  Together with its customers, Elekta ... Forum in Barcelona . The funds ... with the mission to improve cancer care, specifically radiation ... believes that no patient should be denied potentially life-saving ... it cooperates with hospitals and clinics around the world ...
(Date:4/24/2015)... California (PRWEB) April 24, 2015 ... key milestones in its allogeneic stem-cell product development ... to properly reflect the corporate strategic direction. , ... allogeneic (donor) adipose stem cell development program has ... of our cGMP manufacturing facility and hiring of ...
(Date:4/24/2015)... N.J. , April 24, 2015  Navitas Life Sciences ... as Head of Clinical and Regulatory Services. Shalabh is ... been a co-founder and CEO of Kinapse, as well as ... Logo - http://photos.prnewswire.com/prnh/20150423/201261LOGO ... Jim Tizzard commented "I am delighted to welcome Shalabh ...
(Date:4/23/2015)... 23, 2015 The Thomas Brain ... conduct a groundbreaking pilot study to see if ... in as little as three to six months. ... and nutritional medicine—will aggressively target and simultaneously treat ... our aging brain. These include oxidative stress, neuroinflammation, ...
Breaking Biology Technology:Elekta helps raise $33,000 to bring radiation treatment to developing countries 2Elekta helps raise $33,000 to bring radiation treatment to developing countries 3Vet-Stem, Inc. Meets New Milestones and Changes Name to VetStem Biopharma 2Shalabh Kumar Joins Navitas Life Sciences to Lead their Clinical and Regulatory Services Teams 2New Study Looks to Reverse Alzheimer’s Disease 2New Study Looks to Reverse Alzheimer’s Disease 3
... YORK, Aug. 10 ExL Pharma is pleased ... many of the leading issues that are,impacting the ... offer educational and networking opportunities for Clinical,Marketing, R&D, ... biotech and medical technology companies. Listed below ...
... Genmab,s Partner Roche has Filed an IND With the US FDA for ... ... A/S (OMX: GEN),announced today that its partner Roche has filed an Investigational ... antibody developed under the companies, collaboration. Genmab will,receive a milestone payment from ...
... Reliant Pharmaceuticals,Inc. today announced that it has filed ... Exchange Commission for an initial public offering,of its common ... issued common stock and that certain stockholders may sell,a ... Goldman, Sachs & Co. and Merrill Lynch & ...
Cached Biology Technology:Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharma's Fall Line Up! 2Roche Files IND for Second Genmab Antibody 2Reliant Pharmaceuticals Announces the Filing of Registration Statement on Form S-1 For an Initial Public Offering 2
(Date:4/1/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... mobile commerce market, announces the second shipment of a ... early access pre-order customers. Feedback from ... including Walmart, Target, AT&T, Dunkin, Donuts, Stop & Shop ... all outlets and very easy to use. Several users ...
(Date:3/31/2015)... March 31, 2015  Elephant Talk Communications Corp. (NYSE ... provider of Software Defined Network Architecture (ET Software DNA® ... revenue of approximately $20.4 million for the year ended ... million for the year ended December 31, 2013. ... Company had completed its multi-year transition away from its ...
(Date:3/30/2015)... and Markets ( http://www.researchandmarkets.com/research/lc9bnl/global_gesture ) has announced ... in Automotive Sector 2014-2018" report to their offering. ... market in Automotive Sector to grow at a CAGR ... recognition is the ability of a device to identify ... recognition technology can be 2D-based or 3D-based. It uses ...
Breaking Biology News(10 mins):NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2
... as a folk remedy, but now scientists from Britain and ... as a treatment for herpes. The team,s findings, published in ... between two teams to established scientific evidence for traditional medicines. ... across mainland Europe and Asia. From the Middle Ages onwards ...
... OAK RIDGE, Tenn, Feb. 22, 2011 -- A theoretical ... National Laboratory is bringing supercomputer simulations and experimental results ... ORNL,s Jeremy Smith collaborated on devising a method -- ... experiments and computer simulations to strengthen analyses of molecules ...
... Conservation Society (WCS) working in conjunction with the Turtle ... from around the world some of which currently ... hunting for both food and the pet trade along ... in the next decade unless drastic conservation measures are ...
Cached Biology News:Old folk remedy revived: How tansy may be a treatment for herpes 2'Fingerprints' match molecular simulations with reality 2Shellshock: New report lists 25 most endangered turtle species 2
COMING SOON: Anti-Mouse C5/C5b, Clone BB5.1. Monoclonal Antibody...
... Goat anti-Human Alpha 1 Acid ... azide Goats were immunized ... glycoprotein in Freund's adjuvant. ... absorbed to ensure specificity. ...
Anti-Mouse Valpha 2 TCR, Purified (Clone B20.1) (rat IgG2a)...
Request Info...
Biology Products: